GlassScriptPhysician profile
Matthew M White
NPI 1649825696
$3,746.62
in general payments reported to CMS, 2019-2025
18 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $918 · 2022: $1,891 · 2023: $559 · 2024: $197 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $656.65 | 2021-2024 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $577.27 | 2021-2022 | |
| Alkermes, INC. | $509.09 | 2021-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $370.30 | 2021-2023 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $337.10 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $326.44 | 2021-2022 | |
| Abbvie INC. | $224.40 | 2021-2024 | |
| Indivior INC. | $221.11 | 2021-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $109.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $97.91 | 2021-2023 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $71.60 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $70.97 | 2023 | Austedo |
| Idorsia Pharmaceuticals US INC | $57.40 | 2022 | |
| Bausch Health US, LLC | $40.10 | 2021 | |
| Novo Nordisk INC | $22.10 | 2025 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $19.75 | 2023 | Neurostar Tms Therapy System |
| Corium, LLC | $17.71 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $17.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.